Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
Recent advances in mass spectrometry (MS) have enabled extensive analysis of cancer proteomes. Here, we employed quantitative proteomics to profile protein expression across 24 breast cancer patient-derived xenograft (PDX) models. Integrated proteogenomic analysis shows positive correlation between...
Main Author: | Carr, Steven A (Contributor) |
---|---|
Other Authors: | Koch Institute for Integrative Cancer Research at MIT (Contributor) |
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group,
2017-06-19T20:25:53Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
by: Kuan-lin Huang, et al.
Published: (2017-03-01) -
Correction: Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts
by: Kuan-lin Huang, et al.
Published: (2017-04-01) -
Breast cancer quantitative proteome and proteogenomic landscape
by: Henrik J. Johansson, et al.
Published: (2019-04-01) -
Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets
by: Abdulkadir Elmas, et al.
Published: (2021-09-01) -
Proteogenomics: advances in cancer antigen research
by: Takayuki Kanaseki, et al.
Published: (2019-04-01)